Cargando…
Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis
To investigate the clinical characteristics, treatments and prognosis of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions (Xp11.2 tRCC), the epidemiological features and treatment results of 34 cases of Xp11.2 tRCC, which were diagnosed by immunohistochemistry staining of...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125634/ https://www.ncbi.nlm.nih.gov/pubmed/27893792 http://dx.doi.org/10.1371/journal.pone.0166897 |
_version_ | 1782469991883341824 |
---|---|
author | Liu, Ning Wang, Zhen Gan, Weidong Xiong, Lei Miao, Baolei Chen, Xiancheng Guo, Hongqian Li, Dongmei |
author_facet | Liu, Ning Wang, Zhen Gan, Weidong Xiong, Lei Miao, Baolei Chen, Xiancheng Guo, Hongqian Li, Dongmei |
author_sort | Liu, Ning |
collection | PubMed |
description | To investigate the clinical characteristics, treatments and prognosis of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions (Xp11.2 tRCC), the epidemiological features and treatment results of 34 cases of Xp11.2 tRCC, which were diagnosed by immunohistochemistry staining of TFE3 and fluorescence in situ hybridization at our center, were retrospectively reviewed. The 34 patients included 21 females and 13 males aged 3 to 64 years (median age: 27 years). Four patients were children or adolescents (<18 years of age), and 26 patients were young or middle-aged adults (18–45 years). Radical nephrectomy was performed on 25 patients. Laparoscopic nephron-sparing surgery was performed on 9 patients who presented with an isolated mass with a small diameter (<7 cm) and well-defined boundary on computed tomography imaging. Postoperative staging showed that 25 cases (73.53%) were at stage I/II, while 9 cases (26.47%) were at stage III/IV. All stage I/II patients received a favorable prognosis with a three-year overall survival rate of 100%, including the patients who underwent laparoscopic nephron-sparing surgery. With the exception of 2 children, the other 7 stage III/IV patients died or developed recurrence with a median follow-up of 29 months. On univariate analysis, maximum diameter, adjuvant treatment, TNM stage, lymph node metastasis, inferior vena cava tumor thrombosis and tumor boundary were identified as statistically significant factors impacting survival (P<0.05). Multivariate analysis indicated that TNM stage and inferior vena cava tumor thrombosis were independent prognostic factors (P<0.05). In conclusion, Xp11.2 tRCC is a rare subtype of renal cell carcinoma that mainly occurs in young females. Nephron-sparing surgery was confirmed effective preliminarily in the treatment of small Xp11.2 tRCCs with clear rims. Advanced TNM stage and inferior vena cava tumor thrombosis were associated with poor prognosis. |
format | Online Article Text |
id | pubmed-5125634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-51256342016-12-15 Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis Liu, Ning Wang, Zhen Gan, Weidong Xiong, Lei Miao, Baolei Chen, Xiancheng Guo, Hongqian Li, Dongmei PLoS One Research Article To investigate the clinical characteristics, treatments and prognosis of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions (Xp11.2 tRCC), the epidemiological features and treatment results of 34 cases of Xp11.2 tRCC, which were diagnosed by immunohistochemistry staining of TFE3 and fluorescence in situ hybridization at our center, were retrospectively reviewed. The 34 patients included 21 females and 13 males aged 3 to 64 years (median age: 27 years). Four patients were children or adolescents (<18 years of age), and 26 patients were young or middle-aged adults (18–45 years). Radical nephrectomy was performed on 25 patients. Laparoscopic nephron-sparing surgery was performed on 9 patients who presented with an isolated mass with a small diameter (<7 cm) and well-defined boundary on computed tomography imaging. Postoperative staging showed that 25 cases (73.53%) were at stage I/II, while 9 cases (26.47%) were at stage III/IV. All stage I/II patients received a favorable prognosis with a three-year overall survival rate of 100%, including the patients who underwent laparoscopic nephron-sparing surgery. With the exception of 2 children, the other 7 stage III/IV patients died or developed recurrence with a median follow-up of 29 months. On univariate analysis, maximum diameter, adjuvant treatment, TNM stage, lymph node metastasis, inferior vena cava tumor thrombosis and tumor boundary were identified as statistically significant factors impacting survival (P<0.05). Multivariate analysis indicated that TNM stage and inferior vena cava tumor thrombosis were independent prognostic factors (P<0.05). In conclusion, Xp11.2 tRCC is a rare subtype of renal cell carcinoma that mainly occurs in young females. Nephron-sparing surgery was confirmed effective preliminarily in the treatment of small Xp11.2 tRCCs with clear rims. Advanced TNM stage and inferior vena cava tumor thrombosis were associated with poor prognosis. Public Library of Science 2016-11-28 /pmc/articles/PMC5125634/ /pubmed/27893792 http://dx.doi.org/10.1371/journal.pone.0166897 Text en © 2016 Liu et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Liu, Ning Wang, Zhen Gan, Weidong Xiong, Lei Miao, Baolei Chen, Xiancheng Guo, Hongqian Li, Dongmei Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis |
title | Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis |
title_full | Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis |
title_fullStr | Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis |
title_full_unstemmed | Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis |
title_short | Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis |
title_sort | renal cell carcinoma associated with xp11.2 translocation/tfe3 gene fusions: clinical features, treatments and prognosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125634/ https://www.ncbi.nlm.nih.gov/pubmed/27893792 http://dx.doi.org/10.1371/journal.pone.0166897 |
work_keys_str_mv | AT liuning renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis AT wangzhen renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis AT ganweidong renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis AT xionglei renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis AT miaobaolei renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis AT chenxiancheng renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis AT guohongqian renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis AT lidongmei renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis |